Abcam (LON:ABC) had its target price increased by Liberum Capital from GBX 1,290 ($16.97) to GBX 1,370 ($18.02) in a note issued to investors on Wednesday, Stock Target Advisor reports. The brokerage presently has a “hold” rating on the stock. Liberum Capital’s price objective suggests a potential upside of 23.76% from the company’s current price.

A number of other research analysts have also issued reports on the stock. Peel Hunt restated an “add” rating on shares of Abcam in a research note on Wednesday, March 4th. Royal Bank of Canada cut their price target on shares of Abcam from GBX 1,300 ($17.10) to GBX 1,250 ($16.44) and set a “sector performer” rating on the stock in a research note on Wednesday, December 18th. JPMorgan Chase & Co. upped their price target on shares of Abcam from GBX 1,134 ($14.92) to GBX 1,188 ($15.63) and gave the company a “neutral” rating in a research note on Tuesday, March 10th. Finally, Panmure Gordon lowered shares of Abcam to a “sell” rating in a research note on Wednesday, December 18th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company. Abcam presently has a consensus rating of “Hold” and an average price target of GBX 1,345.60 ($17.70).

Abcam stock traded down GBX 94 ($1.24) during mid-day trading on Wednesday, reaching GBX 1,107 ($14.56). 705,539 shares of the company traded hands, compared to its average volume of 497,233. Abcam has a fifty-two week low of GBX 1,058 ($13.92) and a fifty-two week high of GBX 1,523 ($20.03). The company has a market capitalization of $2.28 billion and a price-to-earnings ratio of 50.78. The firm’s fifty day moving average is GBX 1,234.72 and its two-hundred day moving average is GBX 1,259.84.

In other Abcam news, insider Jonathan Simon Milner sold 1,100,000 shares of the company’s stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of GBX 1,412 ($18.57), for a total transaction of £15,532,000 ($20,431,465.40).

About Abcam

Abcam plc, together with its subsidiaries, produces and distributes research-grade antibodies and associated protein research tools worldwide. The company primarily offers primary and secondary antibodies; ELISA, matched antibody pairs and multiplex immunoassays; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex miRNA assays.

Featured Article: What are the Different Types of Leveraged Buyouts?

Analyst Recommendations for Abcam (LON:ABC)

Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.